Expertise in
2
conditions

Tao Bian

299 Qingyang Road, 
Wuxi, CN 
Expertise in
2
conditions
299 Qingyang Road, 
Wuxi, CN 
OverviewLocationsClinical Research

Overview

Tao Bian practices in Wuxi, China. Bian is highly rated in 2 conditions, according to our data. Their top areas of expertise are Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Asthma, Pulmonary Alveolar Proteinosis, and Lung Transplant.

Their clinical research consists of co-authoring 50 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

299 Qingyang Road, Wuxi, 214000, China
Other Locations
Qingyan Road, Wuxi, 214123, China
The Affiliated Drum Tower Hospital Of Nanjing University Medical SchoolNo. 321 Zhongshan Road, Nanjing, 210008, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
A Phase III, 12 Week, Randomized, Double-blind, 4 Arm Parallel Group Bridging Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI Once-daily Via a Dry Powder Inhaler With Dual Combination of FF/VI, Administered in Chinese Participants With Inadequately Controlled Asthma
A Phase III, 12 Week, Randomized, Double-blind, 4 Arm Parallel Group Bridging Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI Once-daily Via a Dry Powder Inhaler With Dual Combination of FF/VI, Administered in Chinese Participants With Inadequately Controlled Asthma
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Device, Drug
Study Drugs: FF/VI, FF/UMEC/VI
Study Phase: Phase 3
A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic Inflammation
A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic Inflammation
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Mepolizumab, Salbutamol
Study Phase: Phase 3
View 2 Less Clinical Trials

50 Total Publications

Cadmium's silent sabotage: unveiling its impact on antibiotic efficacy.
Cadmium's silent sabotage: unveiling its impact on antibiotic efficacy.
Journal: Frontiers in microbiology
Published: July 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Bian's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile